News headlines about Transition Therapeutics (NASDAQ:TTHI) (TSE:TTH) have been trending positive this week, Accern Sentiment reports. The research group identifies negative and positive media coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Transition Therapeutics earned a news impact score of 0.28 on Accern’s scale. Accern also gave news stories about the biopharmaceutical company an impact score of 44.4003538188481 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Transition Therapeutics Company Profile
Transition Therapeutics Inc is a product-focused biopharmaceutical company. The Company’s principal business activity is the researching and developing of therapeutic agents. The Company is developing therapeutics for central nervous system (CNS) and metabolic disease indications. The Company’s technologies are focused on the treatment of agitation and aggression in Alzheimer’s disease and diabetes.
Receive News & Ratings for Transition Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Transition Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.